A phase III clinical trial, called GALILEO, comparing the blood thinner Xarelto to the antiplatelet Plavix with aspirin in patients who have undergone transcatheter aortic valve replacement, was stopped early after a preliminary analysis showed excesses in key adverse events in patients treated with Xarelto. Among patients in the Xarelto group, 11.4 percent suffered thromboembolic events compared to 8.8 percent of patients in the Plavix/aspirin group; and 4.2 percent of Xarelto patients experienced bleeding compared to 2.4 percent of patients in the Plavix/aspirin group. There was also a 6.8 all-cause mortality risk in Xarelto patients compared to 3.3 percent among ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.